Full-Time

Clinical Specialist Representative

Globus Medical

Globus Medical

1,001-5,000 employees

Develops musculoskeletal implants and enabling technologies

No salary listed

Illinois, USA

In Person

Travel up to 70% required.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Robotics

Get referred to Globus Medical

See people who can refer or advise you

Requirements
  • A Bachelor’s Degree with excellent academic achievement is required.
  • A minimum of 2 years of clinical support or relevant healthcare industry experience is required; spine experience is a plus.
  • Knowledge of the operating room environment is required.
  • The candidate must be able to collaborate and influence.
  • Excellent interpersonal, verbal, and written communication skills are required.
  • Experience supporting new and disruptive technologies in a market is a plus.
  • The candidate must be able to travel up to 70%.
  • The employee must be able to sit, climb or balance, and stoop, kneel, crouch or crawl.
  • The employee must regularly lift or move up to 10 pounds and occasionally lift or move up to 25 pounds.
  • The employee must possess close, distance, color, peripheral, and depth vision, along with the capacity to adjust focus.
Responsibilities
  • Develop in-depth technical knowledge of Imaging, Navigation, and Robotics products, applicable procedures, anatomy, and implant products.
  • Provide educational support for new surgeons, operating room staff, and administrators during Imaging, Navigation, and Robotics installations and ongoing customer needs.
  • Provide comprehensive hands-on training to potential and existing customers through cadaver and bio-skill laboratories.
  • Provide ongoing Imaging, Navigation, and Robotics education to Globus Implant peers before capital installation and thereafter.
  • Cultivate surgeon support and generate market awareness around Imaging, Navigation, Robotics products, and affiliated services.
  • Support the installation process and ensure consistent utilization within the initial 90 days.
  • Collaborate with the implant team to identify capital and implant targets to grow the overall business.
  • Assist with the development of key opinion leader surgeons.
  • Manage expenses within budget.
  • Adhere to the company Code of Conduct, the AdvaMed Code, the MedTech Code, and all other company policies.
  • Ensure compliance with applicable governmental laws, rules, and regulations in the United States and internationally by completing introductory and annual training and maintaining role-specific compliance knowledge.
  • Represent the company professionally and uphold high standards of ethical business practices and socially responsible conduct in interactions with employees, customers, suppliers, and other third parties.
Desired Qualifications
  • Spine experience.
  • Experience supporting new and disruptive technologies in a market.

Globus Medical makes medical devices for musculoskeletal issues, especially spine, orthopedic, and neurosurgical care. Its products fall into two groups: Musculoskeletal Solutions with implantable devices, biologics, and surgical instruments, and Enabling Technologies with imaging, navigation, and robotics that help plan, guide, and analyze surgeries. The company stands out by offering an integrated platform that combines implants with enabling technologies to improve surgical precision and outcomes. Its goal is to help patients recover from musculoskeletal problems while expanding its product lines and geographic reach.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Lower Providence Township, Pennsylvania

Founded

2003

Get referred to Globus Medical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 5.9% to $789.6 million, and EPS beat estimates.
  • Management raised 2026 non-GAAP EPS guidance to $4.95-$5.05 after margin expansion.
  • FDA cleared Scripps lumbar spacers and rods in Q2 2026, deepening differentiated product breadth.

What critics are saying

  • Enabling Technologies revenue fell 25.8% in Q2 2026 as flexible financing cannibalized capital sales.
  • Pimenta litigation carries a $43.1 million liability and appeal risk through 2027.
  • Moskowitz and Life Spine patent fights threaten injunctions and royalties, crippling Excelsius growth.

What makes Globus Medical unique

  • Excelsius robotics plus patient-specific Scripps implants create a tightly integrated surgeon workflow.
  • NuVasive integration broadens spine scale; Q2 2026 base revenue grew 9% excluding Nevro.
  • Global direct sales in 64 countries support faster launches and procedure-level pull-through.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 13th, 2026
Globus Medical's fair value trimmed 4% to $103 as analysts lower growth expectations

Globus Medical's assessed fair value has been cut from $107.42 to $103.23, a 3.9% reduction reflecting more cautious growth expectations. Analysts remain divided on the medical device company's prospects. BMO Capital and Wells Fargo highlight strong earnings power, with NuVasive synergies ahead of schedule and Nevro turning accretive faster than expected. Wells Fargo noted Q2 earnings per share of $1.34 exceeded expectations, with management raising 2026 EPS guidance to $4.95–$5.05. However, Stifel slashed its price target from $95 to $80, citing weaker Nevro and Enabling Technologies performance. UBS initiated coverage at Neutral with an $82 target, describing spine market procedure growth as low single digit. The fair value reduction reflects revenue growth trimmed from 6.30% to 5.83%, though profit margins improved from 18.40% to 20.58%.

Yahoo Finance
Aug 7th, 2026
Globus Medical raises EPS guidance to $5.05 despite Nevro and Enabling Tech headwinds

Globus Medical reported second-quarter 2026 non-GAAP earnings per share of $1.34, beating the $1.12 consensus estimate. Revenue of $789.61 million also exceeded expectations of $786.86 million. The company raised full-year EPS guidance to $4.95-$5.05 from $4.70-$4.80 but maintained revenue guidance at $3.18-$3.22 billion. Second-quarter revenue grew 6% overall and 9% excluding Nevro, driven by 7% US Spine growth and 14% International Spine growth. Adjusted gross margin improved to 69.4%, up 200 basis points year-over-year. Adjusted EBITDA margin rose to 35.4% from 28.0%. Management cited Nevro and Enabling Technologies as potential risks to second-half performance. Enabling Technologies revenue fell 25.8% to $26.1 million as the company shifted towards flexible capital-acquisition options.

Associated Press
Aug 6th, 2026
Globus Medical Q2 sales hit $789.6M, non-GAAP EPS jumps 55.8% to $1.34

Globus Medical reported second quarter 2026 worldwide net sales of $789.6 million, up 5.9% year-over-year, or 5.6% on a constant currency basis. GAAP diluted earnings per share fell 26.2% to $1.10, primarily due to a $110.5 million bargain purchase gain from the Nevro acquisition in the prior year quarter. However, non-GAAP diluted EPS rose 55.8% to $1.34. US spine sales grew 7%, whilst international spine sales increased 14% as-reported and 12% on a constant currency basis. Excluding Nevro, overall revenue growth was 9%. The musculoskeletal technology company reaffirmed full-year 2026 revenue guidance of $3.18 billion to $3.22 billion. It raised its non-GAAP fully diluted EPS guidance to $4.95 to $5.05 from the previous range of $4.70 to $4.80.

Yahoo Finance
Jul 21st, 2026
Globus Medical grows 27% as spine device maker raises guidance by 30 cents

Globus Medical reported strong first-quarter 2026 results, with revenue climbing 27% year-over-year to nearly $760 million and earnings per share rising to $1.12 from 68 cents, both exceeding analyst expectations. The $11 billion medical device company, which designs implantable devices and surgical instruments for spinal disorders, attributes growth to expanding market share, operational discipline, and dozens of new product launches. The company's US business has posted three consecutive quarters of at least 10% growth, whilst its international segment and enabling technologies division are also expanding. Following the strong performance, Globus raised its full-year EPS guidance by 30 cents to a range of $4.70-$4.80. The firm continues receiving FDA clearances to expand its product lineup.

Yahoo Finance
Jun 22nd, 2026
Globus Medical shares surge 5.1% after Q1 earnings beat estimates

Globus Medical shares rose 5.1% to $79.23 following strong first-quarter 2026 results. The medical device company posted adjusted earnings per share of $1.12 and revenues of $759.9 million, both exceeding Zacks Consensus Estimates. The company is expected to report quarterly earnings of $1.12 per share in its upcoming report, representing a 30.2% year-on-year increase. Revenues are forecast at $787.34 million, up 5.6% from the previous year. The consensus EPS estimate has been revised 2.5% higher over the past 30 days. Globus Medical currently carries a Zacks Rank #2 (Buy). The stock has declined 10.3% over the past four weeks despite the recent surge.